Gut microbiota are related to Parkinson's disease and clinical phenotype

…, E Pekkonen, E Haapaniemi, S Kaakkola… - Movement …, 2015 - Wiley Online Library
In the course of Parkinson's disease (PD), the enteric nervous system (ENS) and parasympathetic
nerves are amongst the structures earliest and most frequently affected by alpha‐…

Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors

PT Männistö, S Kaakkola - Pharmacological reviews, 1999 - ASPET
Axelrod et al.(1958) first described the enzyme-catalyzed O-methylation of catecholamines
and other catechols in the late 1950s. The enzyme responsible for the O-methylation, catechol…

A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology

…, L Myllykangas, M Siitonen, A Raunio, S Kaakkola… - Neurobiology of …, 2014 - Elsevier
We describe the clinical, neuropathological, and genetic features of a Finnish patient with a
novel α-synuclein (SNCA) mutation A53E. The patient was clinically diagnosed with atypical …

[PDF][PDF] Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin

…, A Löfgren, P Hackman, A Paetau, S Kaakkola… - The American Journal of …, 2005 - cell.com
Mutations in the catalytic subunit of the mitochondrial DNA polymerase γ (POLG) have been
found to be an important cause of neurological disease. Recently, we and collaborators …

A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia

T Odergren, H Hjaltason, S Kaakkola… - Journal of Neurology …, 1998 - jnnp.bmj.com
OBJECTIVE This study was designed to establish whether a ratio of three units of Dysport ®
is equivalent to one unit of Botox ® for the treatment of cervical dystonia. METHODS Patients …

POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement

…, P Luoma, M Rantamaki, A Al Memar, S Kaakkola… - Neurology, 2004 - AAN Enterprises
Objective: To identify POLG mutations in patients with sensory ataxia and CNS features.
Methods: The authors characterized clinical, laboratory, and molecular genetic features in eight …

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease

S Kaakkola - Drugs, 2000 - Springer
When peripheral decarboxylation is blocked by carbidopa or benserazide, the main
metabolic pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT). …

Defective cortical drive to muscle in Parkinson's disease and its improvement with levodopa

S Salenius, S Avikainen, S Kaakkola, R Hari, P Brown - Brain, 2002 - academic.oup.com
We recorded whole‐scalp magnetoencephalographic (MEG) signals simultaneously with
surface electromyographic (EMG) activity from eight patients with Parkinson’s disease after …

Economic burden and quality of life impairment increase with severity of PD

T Keränen, S Kaakkola, K Sotaniemi… - Parkinsonism & related …, 2003 - Elsevier
Purpose. To define the interrelationship between cost-of-illness, quality of life (QoL) and
Parkinson's disease (PD) severity in a common patient management setting in Finland. Scope. …

Laminin is induced in astrocytes of adult brain by injury.

P Liesi, S Kaakkola, D Dahl, A Vaheri - The EMBO journal, 1984 - embopress.org
Laminin is a high mol. wt. non‐collagenous matrix glycoprotein, confined in adult tissues to
basement membranes. In normal rat brain we found laminin mainly in vessel walls but, after …